CervoMed’s (CRVO) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of CervoMed (NASDAQ:CRVO) in a report published on Wednesday,Benzinga reports. They currently have a $31.00 price target on the stock.

CRVO has been the subject of a number of other reports. Cantor Fitzgerald began coverage on CervoMed in a research report on Thursday, December 18th. They issued an “overweight” rating for the company. Brookline Capital Acquisition raised CervoMed to a “strong-buy” rating in a research note on Tuesday, February 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of CervoMed in a report on Wednesday, January 21st. Zacks Research upgraded shares of CervoMed from a “strong sell” rating to a “hold” rating in a research report on Monday, January 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of CervoMed in a report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.17.

CervoMed Trading Up 2.5%

Shares of NASDAQ:CRVO opened at $4.11 on Wednesday. The company has a 50 day moving average of $5.83 and a 200-day moving average of $7.50. The firm has a market cap of $38.02 million, a P/E ratio of -1.42 and a beta of -0.77. CervoMed has a twelve month low of $1.92 and a twelve month high of $16.94.

Institutional Investors Weigh In On CervoMed

A number of institutional investors and hedge funds have recently modified their holdings of CRVO. Vanguard Group Inc. lifted its holdings in shares of CervoMed by 1.0% during the third quarter. Vanguard Group Inc. now owns 343,463 shares of the company’s stock valued at $2,779,000 after purchasing an additional 3,445 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in CervoMed by 8,425,900.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 84,260 shares of the company’s stock worth $666,000 after purchasing an additional 84,259 shares in the last quarter. Jane Street Group LLC acquired a new stake in CervoMed during the 2nd quarter worth about $414,000. Citizens Financial Group Inc. RI lifted its stake in CervoMed by 23.0% during the fourth quarter. Citizens Financial Group Inc. RI now owns 37,477 shares of the company’s stock valued at $296,000 after buying an additional 7,000 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in CervoMed during the third quarter valued at about $247,000. 25.15% of the stock is owned by institutional investors and hedge funds.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.